Vaccinia virus vaccines

Past, present and future

Bertram Jacobs, Jeffrey Langland, Karen Kibler, Karen L. Denzler, Stacy D. White, Susan A. Holechek, Shukmei Wong, Trung Huynh, Carole R. Baskin

Research output: Contribution to journalArticle

111 Citations (Scopus)

Abstract

Vaccinia virus (VACV) has been used more extensively for human immunization than any other vaccine. For almost two centuries, VACV was employed to provide cross-protection against variola virus, the causative agent of smallpox, until the disease was eradicated in the late 1970s. Since that time, continued research on VACV has produced a number of modified vaccines with improved safety profiles. Attenuation has been achieved through several strategies, including sequential passage in an alternative host, deletion of specific genes or genetic engineering of viral genes encoding immunomodulatory proteins. Some highly attenuated third- and fourth-generation VACV vaccines are now being considered for stockpiling against a possible re-introduction of smallpox through bioterrorism. Researchers have also taken advantage of the ability of the VACV genome to accommodate additional genetic material to produce novel vaccines against a wide variety of infectious agents, including a recombinant VACV encoding the rabies virus glycoprotein that is administered orally to wild animals. This review provides an in-depth examination of these successive generations of VACV vaccines, focusing on how the understanding of poxviral replication and viral gene function permits the deliberate modification of VACV immunogenicity and virulence.

Original languageEnglish (US)
Pages (from-to)1-13
Number of pages13
JournalAntiviral Research
Volume84
Issue number1
DOIs
StatePublished - Oct 2009

Fingerprint

Vaccinia virus
Vaccines
Smallpox
Viral Genes
Variola virus
Cross Protection
Bioterrorism
Rabies virus
Wild Animals
Genetic Engineering
Gene Deletion
Virulence
Immunization
Glycoproteins
Research Personnel
Genome
Safety
Research

Keywords

  • Biodefense
  • Orthopoxvirus
  • Poxvirus
  • Smallpox
  • Vaccination complications
  • Vaccine vector
  • Vaccinia E3L
  • Vaccinia virus

ASJC Scopus subject areas

  • Virology
  • Pharmacology

Cite this

Vaccinia virus vaccines : Past, present and future. / Jacobs, Bertram; Langland, Jeffrey; Kibler, Karen; Denzler, Karen L.; White, Stacy D.; Holechek, Susan A.; Wong, Shukmei; Huynh, Trung; Baskin, Carole R.

In: Antiviral Research, Vol. 84, No. 1, 10.2009, p. 1-13.

Research output: Contribution to journalArticle

Jacobs, B, Langland, J, Kibler, K, Denzler, KL, White, SD, Holechek, SA, Wong, S, Huynh, T & Baskin, CR 2009, 'Vaccinia virus vaccines: Past, present and future', Antiviral Research, vol. 84, no. 1, pp. 1-13. https://doi.org/10.1016/j.antiviral.2009.06.006
Jacobs, Bertram ; Langland, Jeffrey ; Kibler, Karen ; Denzler, Karen L. ; White, Stacy D. ; Holechek, Susan A. ; Wong, Shukmei ; Huynh, Trung ; Baskin, Carole R. / Vaccinia virus vaccines : Past, present and future. In: Antiviral Research. 2009 ; Vol. 84, No. 1. pp. 1-13.
@article{6e6636c9d32843b0a614b8e804b5ffe7,
title = "Vaccinia virus vaccines: Past, present and future",
abstract = "Vaccinia virus (VACV) has been used more extensively for human immunization than any other vaccine. For almost two centuries, VACV was employed to provide cross-protection against variola virus, the causative agent of smallpox, until the disease was eradicated in the late 1970s. Since that time, continued research on VACV has produced a number of modified vaccines with improved safety profiles. Attenuation has been achieved through several strategies, including sequential passage in an alternative host, deletion of specific genes or genetic engineering of viral genes encoding immunomodulatory proteins. Some highly attenuated third- and fourth-generation VACV vaccines are now being considered for stockpiling against a possible re-introduction of smallpox through bioterrorism. Researchers have also taken advantage of the ability of the VACV genome to accommodate additional genetic material to produce novel vaccines against a wide variety of infectious agents, including a recombinant VACV encoding the rabies virus glycoprotein that is administered orally to wild animals. This review provides an in-depth examination of these successive generations of VACV vaccines, focusing on how the understanding of poxviral replication and viral gene function permits the deliberate modification of VACV immunogenicity and virulence.",
keywords = "Biodefense, Orthopoxvirus, Poxvirus, Smallpox, Vaccination complications, Vaccine vector, Vaccinia E3L, Vaccinia virus",
author = "Bertram Jacobs and Jeffrey Langland and Karen Kibler and Denzler, {Karen L.} and White, {Stacy D.} and Holechek, {Susan A.} and Shukmei Wong and Trung Huynh and Baskin, {Carole R.}",
year = "2009",
month = "10",
doi = "10.1016/j.antiviral.2009.06.006",
language = "English (US)",
volume = "84",
pages = "1--13",
journal = "Antiviral Research",
issn = "0166-3542",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Vaccinia virus vaccines

T2 - Past, present and future

AU - Jacobs, Bertram

AU - Langland, Jeffrey

AU - Kibler, Karen

AU - Denzler, Karen L.

AU - White, Stacy D.

AU - Holechek, Susan A.

AU - Wong, Shukmei

AU - Huynh, Trung

AU - Baskin, Carole R.

PY - 2009/10

Y1 - 2009/10

N2 - Vaccinia virus (VACV) has been used more extensively for human immunization than any other vaccine. For almost two centuries, VACV was employed to provide cross-protection against variola virus, the causative agent of smallpox, until the disease was eradicated in the late 1970s. Since that time, continued research on VACV has produced a number of modified vaccines with improved safety profiles. Attenuation has been achieved through several strategies, including sequential passage in an alternative host, deletion of specific genes or genetic engineering of viral genes encoding immunomodulatory proteins. Some highly attenuated third- and fourth-generation VACV vaccines are now being considered for stockpiling against a possible re-introduction of smallpox through bioterrorism. Researchers have also taken advantage of the ability of the VACV genome to accommodate additional genetic material to produce novel vaccines against a wide variety of infectious agents, including a recombinant VACV encoding the rabies virus glycoprotein that is administered orally to wild animals. This review provides an in-depth examination of these successive generations of VACV vaccines, focusing on how the understanding of poxviral replication and viral gene function permits the deliberate modification of VACV immunogenicity and virulence.

AB - Vaccinia virus (VACV) has been used more extensively for human immunization than any other vaccine. For almost two centuries, VACV was employed to provide cross-protection against variola virus, the causative agent of smallpox, until the disease was eradicated in the late 1970s. Since that time, continued research on VACV has produced a number of modified vaccines with improved safety profiles. Attenuation has been achieved through several strategies, including sequential passage in an alternative host, deletion of specific genes or genetic engineering of viral genes encoding immunomodulatory proteins. Some highly attenuated third- and fourth-generation VACV vaccines are now being considered for stockpiling against a possible re-introduction of smallpox through bioterrorism. Researchers have also taken advantage of the ability of the VACV genome to accommodate additional genetic material to produce novel vaccines against a wide variety of infectious agents, including a recombinant VACV encoding the rabies virus glycoprotein that is administered orally to wild animals. This review provides an in-depth examination of these successive generations of VACV vaccines, focusing on how the understanding of poxviral replication and viral gene function permits the deliberate modification of VACV immunogenicity and virulence.

KW - Biodefense

KW - Orthopoxvirus

KW - Poxvirus

KW - Smallpox

KW - Vaccination complications

KW - Vaccine vector

KW - Vaccinia E3L

KW - Vaccinia virus

UR - http://www.scopus.com/inward/record.url?scp=69249206610&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69249206610&partnerID=8YFLogxK

U2 - 10.1016/j.antiviral.2009.06.006

DO - 10.1016/j.antiviral.2009.06.006

M3 - Article

VL - 84

SP - 1

EP - 13

JO - Antiviral Research

JF - Antiviral Research

SN - 0166-3542

IS - 1

ER -